Item 2.02 Results of Operations and Financial Condition.

Although it has not finalized its full financial results for the quarter ended June 30, 2021, Precision BioSciences, Inc. (the "Company") expects to report that it had $174 million in cash and cash equivalents as of June 30, 2021. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of June 30, 2021 and its results of operations for the three and six months then ended. The review of the Company's financial statements for the three and six months ended June 30, 2021 by the Company's independent registered public accounting firm is ongoing and could result in changes to the information set forth above.

The information contained in this Item 2.02 of the Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01.Regulation FD Disclosure.

The Company will be participating in various meetings with investors and analysts, and a copy of the Company's corporate deck being used at these meetings is available in the "Investors & Media" portion of the Company's website at https://investor.precisionbiosciences.com.







Forward-Looking Statements

Statements in this Current Report on Form 8-K regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited, to statements regarding Company's expected cash balance. Forward-looking statements may be identified by words such as "anticipates," "believe," "continue," "expect," "intend," "may," "plan to," "potential," "projects," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, as such factors may be updated from time to time in the Company's other filings with the Securities and Exchange Commission ("SEC"), which filings are accessible on the SEC's website at www.sec.gov and the Investors & Media page of the Company's website at https://investor.precisionbiosciences.com. All forward-looking statements speak only as of the date of this Current Report on Form 8-K and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses